Royal Bank of Canada’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.16M | Buy |
16,181
+9,176
| +131% | +$522K | ﹤0.01% | 3509 |
|
|
2025
Q4 | $296K | Sell |
7,005
-32,316
| -82% | -$1.81M | ﹤0.01% | 4518 |
|
|
2025
Q3 | $2.24M | Buy |
39,321
+21,544
| +121% | +$713K | ﹤0.01% | 3314 |
|
|
2025
Q2 | $460K | Buy |
17,777
+16,886
| +1,895% | +$190K | ﹤0.01% | 4537 |
|
|
2025
Q1 | $9K | Sell |
891
-1,023
| -53% | -$13.4K | ﹤0.01% | 6193 |
|
|
2024
Q4 | $26K | Buy |
1,914
+669
| +54% | +$11.8K | ﹤0.01% | 6005 |
|
|
2024
Q3 | $24K | Buy |
1,245
+103
| +9% | +$1.96K | ﹤0.01% | 6035 |
|
|
2024
Q2 | $21K | Buy |
1,142
+1,119
| +4,865% | +$23.6K | ﹤0.01% | 6058 |
|
|
2024
Q1 | $0 | Sell |
23
-26
| -53% | -$272 | ﹤0.01% | 7400 |
|
|
2023
Q4 | $0 | Buy |
49
+42
| +600% | +$318 | ﹤0.01% | 7428 |
|
|
2023
Q3 | $0 | Sell |
7
-18
| -72% | -$173 | ﹤0.01% | 7401 |
|
|
2023
Q2 | $0 | Sell |
25
-798
| -97% | -$8.51K | ﹤0.01% | 7524 |
|
|
2023
Q1 | $8K | Sell |
823
-1,557
| -65% | -$47.1K | ﹤0.01% | 6415 |
|
|
2022
Q4 | $80K | Buy |
2,380
+1,339
| +129% | +$64.8K | ﹤0.01% | 5618 |
|
|
2022
Q3 | $50K | Buy |
1,041
+482
| +86% | +$28.7K | ﹤0.01% | 5738 |
|
|
2022
Q2 | $32K | Sell |
559
-369
| -40% | -$23.3K | ﹤0.01% | 5912 |
|
|
2022
Q1 | $75K | Buy |
928
+660
| +246% | +$97.7K | ﹤0.01% | 5831 |
|
|
2021
Q4 | $55K | Sell |
268
-807
| -75% | -$175K | ﹤0.01% | 6323 |
|
|
2021
Q3 | $290K | Buy |
1,075
+136
| +14% | +$32.7K | ﹤0.01% | 4811 |
|
|
2021
Q2 | $242K | Buy |
939
+572
| +156% | +$158K | ﹤0.01% | 4916 |
|
|
2021
Q1 | $110K | Sell |
367
-735
| -67% | -$229K | ﹤0.01% | 5392 |
|
|
2020
Q4 | $281K | Buy |
1,102
+283
| +35% | +$73.1K | ﹤0.01% | 4600 |
|
|
2020
Q3 | $204K | Sell |
819
-279
| -25% | -$87.8K | ﹤0.01% | 4542 |
|
|
2020
Q2 | $381K | Sell |
1,098
-1,065
| -49% | -$332K | ﹤0.01% | 3991 |
|
|
2020
Q1 | $579K | Buy |
2,163
+1,016
| +89% | +$314K | ﹤0.01% | 3480 |
|
|
2019
Q4 | $372K | Sell |
1,147
-3,352
| -75% | -$972K | ﹤0.01% | 4188 |
|
|
2019
Q3 | $1.23M | Buy |
4,499
+320
| +8% | +$117K | ﹤0.01% | 3182 |
|
|
2019
Q2 | $2.23M | Buy |
4,179
+580
| +16% | +$291K | ﹤0.01% | 2665 |
|
|
2019
Q1 | $1.81M | Buy |
3,599
+1,805
| +101% | +$1.07M | ﹤0.01% | 2762 |
|
|
2018
Q4 | $885K | Buy |
1,794
+427
| +31% | +$258K | ﹤0.01% | 3261 |
|
|
2018
Q3 | $1.25M | Buy |
1,367
+490
| +56% | +$418K | ﹤0.01% | 3191 |
|
|
2018
Q2 | $642K | Sell |
877
-5,772
| -87% | -$6.66M | ﹤0.01% | 3594 |
|
|
2018
Q1 | $10.6M | Buy |
6,649
+6,491
| +4,108% | +$8.36M | ﹤0.01% | 1496 |
|
|
2017
Q4 | $142K | Sell |
158
-822
| -84% | -$486K | ﹤0.01% | 4613 |
|
|
2017
Q3 | $353K | Buy |
980
+823
| +524% | +$257K | ﹤0.01% | 4079 |
|
|
2017
Q2 | $46K | Sell |
157
-893
| -85% | -$258K | ﹤0.01% | 5160 |
|
|
2017
Q1 | $369K | Sell |
1,050
-96
| -8% | -$21.6K | ﹤0.01% | 3888 |
|
|
2016
Q4 | $212K | Buy |
1,146
+1,101
| +2,447% | +$224K | ﹤0.01% | 4449 |
|
|
2016
Q3 | $12K | Sell |
45
-1,529
| -97% | -$394K | ﹤0.01% | 5726 |
|
|
2016
Q2 | $336K | Sell |
1,574
-1,955
| -55% | -$437K | ﹤0.01% | 4018 |
|
|
2016
Q1 | $728K | Buy |
3,529
+1,664
| +89% | +$320K | ﹤0.01% | 3341 |
|
|
2015
Q4 | $472K | Sell |
1,865
-1,363
| -42% | -$280K | ﹤0.01% | 3835 |
|
|
2015
Q3 | $531K | Sell |
3,228
-286
| -8% | -$50.6K | ﹤0.01% | 3435 |
|
|
2015
Q2 | $660K | Buy |
3,514
+286
| +9% | +$49.2K | ﹤0.01% | 3325 |
|
|
2015
Q1 | $533K | Sell |
3,228
-145
| -4% | -$29.8K | ﹤0.01% | 3447 |
|
|
2014
Q4 | $785K | Buy |
3,373
+155
| +5% | +$33.1K | ﹤0.01% | 3132 |
|
|
2014
Q3 | $583K | Sell |
3,218
-1,980
| -38% | -$379K | ﹤0.01% | 3317 |
|
|
2014
Q2 | $1M | Sell |
5,198
-59
| -1% | -$10.4K | ﹤0.01% | 2838 |
|
|
2014
Q1 | $956K | Buy |
5,257
+4,524
| +617% | +$895K | ﹤0.01% | 2801 |
|
|
2013
Q4 | $125K | Buy |
733
+60
| +9% | +$9.68K | ﹤0.01% | 4457 |
|
|
2013
Q3 | $105K | Sell |
673
-287
| -30% | -$53.1K | ﹤0.01% | 4450 |
|
|
2013
Q2 | $167K | Buy |
+960
| New | +$147K | ﹤0.01% | 4001 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
Royal Bank of Canada's NKTR Position: Q1 2026 in Review
Royal Bank of Canada increased its Nektar Therapeutics (NKTR) stake by 131% in Q1 2026, buying an estimated $522K and bringing the position to 16,181 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3509.
Royal Bank of Canada first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.6M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- Royal Bank of Canada held 16,181 shares of Nektar Therapeutics worth $1.16M as of Q1 2026.
- Royal Bank of Canada bought 9,176 Nektar Therapeutics shares in Q1 2026, an estimated $522K.
- Nektar Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3509 holding.
- Royal Bank of Canada first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Royal Bank of Canada's Nektar Therapeutics position peaked at $10.6M in Q1 2018.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.